Xilio director receives 5,000 share option grant
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Xilio Therapeutics director Aoife Brennan received a new stock option grant. The award covers 5,000 shares of common stock at an exercise price of $7.99 per share, expiring on June 10, 2036. It vests 100% on June 11, 2027 or at the next annual stockholder meeting, subject to continued service.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 5,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Key Figures
Key Terms
Stock Option (right to buy) financial
Grant, award, or other acquisition financial
exercise price financial
vesting financial
annual meeting of stockholders financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Xilio Therapeutics (XLO) report for Aoife Brennan?
What is the exercise price and expiration date of Aoife Brennan’s Xilio (XLO) options?
When do Aoife Brennan’s Xilio Therapeutics (XLO) options vest?
Is Aoife Brennan’s Xilio (XLO) Form 4 transaction an open-market stock purchase?
AI-generated analysis. How Rhea-AI works. Not financial advice.